DE60042700D1 - Integrin-vermittelte arzneimittel-zielrichtung - Google Patents

Integrin-vermittelte arzneimittel-zielrichtung

Info

Publication number
DE60042700D1
DE60042700D1 DE60042700T DE60042700T DE60042700D1 DE 60042700 D1 DE60042700 D1 DE 60042700D1 DE 60042700 T DE60042700 T DE 60042700T DE 60042700 T DE60042700 T DE 60042700T DE 60042700 D1 DE60042700 D1 DE 60042700D1
Authority
DE
Germany
Prior art keywords
sub
integrin
medicined
target direction
cytostatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60042700T
Other languages
English (en)
Inventor
Hans-Georg Lerchen
Joerg Baumgarten
Ulf Brueggemeier
Markus Albers
Andreas Schoop
Thomas-J Schulze
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE60042700D1 publication Critical patent/DE60042700D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60042700T 1999-09-08 2000-08-28 Integrin-vermittelte arzneimittel-zielrichtung Expired - Lifetime DE60042700D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39216799A 1999-09-08 1999-09-08
US60677200A 2000-06-29 2000-06-29
PCT/EP2000/008361 WO2001017563A2 (en) 1999-09-08 2000-08-28 Integrin-mediated drug targeting

Publications (1)

Publication Number Publication Date
DE60042700D1 true DE60042700D1 (de) 2009-09-17

Family

ID=27013781

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60042700T Expired - Lifetime DE60042700D1 (de) 1999-09-08 2000-08-28 Integrin-vermittelte arzneimittel-zielrichtung

Country Status (16)

Country Link
US (1) US20060189544A1 (de)
EP (1) EP1235595B8 (de)
JP (1) JP2003508497A (de)
CN (1) CN1402643A (de)
AT (1) ATE438413T1 (de)
AU (1) AU773781B2 (de)
BR (1) BR0013883A (de)
CA (1) CA2383981A1 (de)
DE (1) DE60042700D1 (de)
ES (1) ES2330079T3 (de)
HU (1) HUP0203899A3 (de)
MX (1) MXPA02002488A (de)
NZ (1) NZ517620A (de)
PL (1) PL354268A1 (de)
RU (1) RU2002109215A (de)
WO (1) WO2001017563A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1219305A1 (de) * 2000-12-27 2002-07-03 Bayer Aktiengesellschaft Konjugate von Integrinrezeptorantagonisten und einem zytostatischen Mittel mit spezifisch spaltbaren Linkergruppen
EP1238678A1 (de) * 2001-03-08 2002-09-11 Bayer Aktiengesellschaft Enzymaktivierte cytostatische Prodrugverbindungen mit Integrin Liganden
ITRM20040240A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 7 con antagonisti delle integrine.
ITRM20040241A1 (it) * 2004-05-13 2004-08-13 Ist Naz Stud Cura Dei Tumori Camptotecine coniugate in posizione 20 con antagonisti delle integrine.
CN105566338B (zh) * 2014-10-08 2017-11-21 兰州大学 一种喜树碱类化合物及其制备方法和用途
CN108456154A (zh) * 2018-04-13 2018-08-28 昆明理工大学 一种n-叔丁氧羰基烃基胍的制备方法
WO2023057813A1 (en) * 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders
WO2023057814A1 (en) * 2021-10-04 2023-04-13 Vincerx Pharma Gmbh Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE175241T1 (de) * 1992-04-03 1999-01-15 Genentech Inc Antikörper gegen alpha v beta 3 integrin
WO1997039021A1 (en) * 1995-12-21 1997-10-23 The Scripps Research Institute Targeted therapeutic or diagnostic agents and methods of making and using same

Also Published As

Publication number Publication date
MXPA02002488A (es) 2002-08-12
RU2002109215A (ru) 2003-12-10
AU773781B2 (en) 2004-06-03
HUP0203899A2 (hu) 2003-02-28
NZ517620A (en) 2004-02-27
CN1402643A (zh) 2003-03-12
EP1235595B1 (de) 2009-08-05
AU7648700A (en) 2001-04-10
PL354268A1 (en) 2003-12-29
ES2330079T3 (es) 2009-12-04
EP1235595A2 (de) 2002-09-04
WO2001017563A3 (en) 2002-07-11
JP2003508497A (ja) 2003-03-04
WO2001017563A2 (en) 2001-03-15
CA2383981A1 (en) 2001-03-15
EP1235595B8 (de) 2009-10-07
ATE438413T1 (de) 2009-08-15
BR0013883A (pt) 2002-05-07
US20060189544A1 (en) 2006-08-24
HUP0203899A3 (en) 2004-09-28

Similar Documents

Publication Publication Date Title
ZA969489B (en) Novel transfection agents and their pharmaceutical applications
BR9812634A (pt) April - uma proteìna com efeitos de crescimento
TR200001399T2 (tr) Siklik amin türevleri ve ilaç olarak kullanımları.
ATE349976T1 (de) Mikrostruktur-stentstruktur
AU2845599A (en) Pharmaceutical compositions and their use
ATE277923T1 (de) Propansäurederivate, die die bindung von integrinen an ihre rezeptoren behindern
BR0015256A (pt) Composições farmacêuticas contendo uma droga de antibiótico de fluoroquinolona e uma goma de xantano
BR9909486A (pt) Compostos calcilìticos
TR200200359T2 (tr) Cgrp Antagonist'lerinin ve cgrp-release (Gevşeme)-Engelleyici Menopoza Bağlı Deri Kızarıklıklarında Kullanılması
NO20013517L (no) Makrolider med anti-inflammatorisk aktivitet
DE60042700D1 (de) Integrin-vermittelte arzneimittel-zielrichtung
BR0209440A (pt) Sulfonamidas
IT8919193A0 (it) Derivati imidazolonici ad attivita' antiipertensiva, loro metodi di preparazione e composizioni farmaceutiche che li contengono.
BG105885A (en) Remedies for joint diseases
YU72194A (sh) Injekcione suspenzije sa produženim dejstvom i postupak za proizvodnju istih
ES2167939T3 (es) Nuevas poliaminas, su preparacion y usos.
IT1270618B (it) Proteine ad attivita' antitumorale
ATE201680T1 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze
SE9902056D0 (sv) An integrin heterodimer and an alpha subunit thereof
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
ES2133918T3 (es) Nuevos esteroides seco-d activos en el sistema cardiovascular y composiciones farmaceuticas que los contienen.
TR200103827T2 (tr) Farmakolojik kompleks
IT1306147B1 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali
DE50015195D1 (de) Feste paroxetin enthaltende zubereitungen
DE69804674T2 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, 1335, DE

8364 No opposition during term of opposition